Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:09 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination
NCT04868877 · Merus B.V. · PHASE1/PHASE2 · terminated · last registry update 2026-10-26 · Non-small cell lung cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The Sponsor terminated the trial early for strategic business reasons. This isn't related to any safety/efficacy/clinical activity/benefit-risk concern with petosemtamab. Ongoing participants will have access to treatment outside of this trial.” | – | Registry record, Merus B.V. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against EGFR in non-small cell lung cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-10-27Phase 3 first posted: Jiangsu Aosaikang Pharmaceutical Co., Ltd., ASKC202 + ASKC202 placebo (NCT07897188)
- 2026-10-08Also stopped (terminated): Jin Hyoung Kang, Lazertinib + Pemetrexed (NCT05477615)
- 2026-09-21Also stopped (terminated): Massachusetts General Hospital, Niraparib + Osimertinib (NCT03891615)
- 2026-09-15Also stopped (withdrawn): Roswell Park Cancer Institute, Cemiplimab + Cetuximab Sarotalocan Sodium (NCT06943664)
- 2026-07-31Phase 3 first posted: National Taiwan University Hospital, Osimertinib (NCT07738172)
- 2026-07-02Phase 3 first posted: Bristol-Myers Squibb, Iza-bren + Osimertinib (NCT07680790)
- 2026-06-12Results posted on the registry: Spectrum Pharmaceuticals, Inc, Poziotinib (NCT03318939)
- 2026-06-12Also stopped (terminated): Spectrum Pharmaceuticals, Inc, Poziotinib (NCT03318939)
- 2026-06-11Phase 3 first posted: Sichuan Baili Pharmaceutical Co., Ltd., BL-B01D1 + Osimertinib (NCT07640789)
- 2026-06-11Phase 3 first posted: Sichuan Baili Pharmaceutical Co., Ltd., BL-B01D1 + Osimertinib (NCT07642024)
- 2026-06-05Results posted on the registry: AstraZeneca, Osimertinib + Cisplatin (NCT04351555)
- 2026-06-03Also stopped (terminated): Petrov, Andrey, Afatinib Dimaleat + inhalation of afatinib dimaleate (NCT06897735)
- 2026-04-27Also stopped (terminated): Partner Therapeutics, Inc., Afatinib Oral Tablet + Enzalutamide Pill (NCT05588609)
- 2026-04-23Also stopped (terminated): National Cancer Institute (NCI), Alectinib + Brigatinib (NCT03737994)
- 2026-03-17Results posted on the registry: National Cancer Institute (NCI), Bevacizumab + Osimertinib (NCT02971501)
- 2026-02-02Results posted on the registry: Janssen Research & Development, LLC, Lazertinib + Amivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF) (NCT05388669)
- 2026-01-29Phase 3 first posted: CSPC Megalith Biopharmaceutical Co.,Ltd., SYS6010 + Osimertinib (NCT07376382)
- 2026-01-13Results posted on the registry: AstraZeneca, Osimertinib (AZD9291) pemetrexed cisplatin or carboplatin + Placebo for osimertinib (AZD9291) pemetrexed cisplatin or carboplatin (NCT04765059)
- 2025-10-31Results posted on the registry: European Organisation for Research and Treatment of Cancer - EORTC, Osimertinib + Gefitinib (NCT02856893)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision